Sign In
ATHA.US
id: 683

Athira (ATHA) $10M IPO & SPO Settlement

W.D. Washington
Court
2:21-cv-00861
Case number
17 Sept 2020
Class period Start
17 Jun 2021
Class period End
06 Sept 2024
Claim deadline
Athira (ATHA) agreed to settle $10 million with Investors to end claims over IPO in 2020 and SPO in 2021.
Case Status
Accepting Claims
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Investment Bank
Service Provider
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.47
Filing date
25 June 2021
Plaintiffs
Wies Rafi, Antonio Bachaalani Nacif
Attorneys
Glancy Prongay & Murray LLP (Los Angeles, CA), Labaton Sucharow LLP (New York, NY), Rossi Vucinovich, P.C. (Seattle, WA)
Defendants
Kawas, Glenna Mileson, Joseph Edelman,
Judge
Hon. Thomas S. Zilly
Administrator
Strategic Claims Services
Settlement agreement date
2023-04-27
Trades matching type
FIFO
+$10,000,000
Cash Settlement Amount

Athira Pharma Inc

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgo...

    Ticker
    ATHA.US
    ISIN
    US04746L1044
    CIK
    1620463
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    18706 North Creek Parkway, Bothell, WA, United States, 98011